anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
Fluid and electrolyte depletion often occur in patients who have diarrhea. In such cases, administration of appropriate fluid and electrolytes is very important. The use of loperamide hydrochloride does not preclude the need for appropriate fluid and electrolyte therapy.

In general, loperamide hydrochloride should not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon. Loperamide hydrochloride must be discontinued promptly when constipation, abdominal distention or ileus develop.

Treatment of diarrhea with loperamide hydrochloride is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate (or when indicated).

Patients with AIDS treated with loperamide hydrochloride for diarrhea should have therapy stopped at the earliest signs of abdominal distention. There have been isolated reports of toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide hydrochloride. {ref EDMS-PSDB-2564186, p. 12}

Loperamide hydrochloride should be used with special caution in young children because of the greater variability of response in this age group. Dehydration, particularly in younger children, may further influence the variability of response to loperamide hydrochloride.
BACKGROUND: Over 8 million children with disabilities live in Africa and are candidates for augmentative and alternative communication (AAC), yet formal training for team members, such as speech-language therapists and special education teachers, is extremely limited. Only one university on the continent provides postgraduate degrees in AAC, and other institutions provide only short modules at an undergraduate level. The need for an introductory training course on AAC that is accessible by university students continent-wide was identified. An online programme, namely an intelligent tutoring system (ITS), was identified as a possible option to facilitate interactive learning without the need for synchronous teaching. The use of an ITS is shown to be effective in developing knowledge and clinical reasoning in the health and rehabilitation fields. However, it has not yet been applied to student teaching in the field of AAC.
AIM: To determine both the feasibility of an ITS to implement an AAC curriculum for students in four African countries, and the usability and effectiveness of such a system as a mechanism for learning about AAC.
METHOD & PROCEDURES: The study included two components: the development of a valid AAC curriculum; and using the ITS to test the effectiveness of implementation in a pre- and post-test design with 98 speech-language therapy and special education students from five universities.
OUTCOMES & RESULTS: Statistically significant differences were obtained between pre- and post-test assessments. Students perceived the learning experience as practical, with rich content.
CONCLUSIONS & IMPLICATIONS: The findings suggest that the ITS-based AAC curriculum was positively perceived by the students and potentially offers an effective means of providing supplementary AAC training to students, although modifications to the system are still required.
WHAT THIS PAPER ADDS: What is already known on the subject Professionals typically lack formal training in AAC. In Africa, this presents a serious challenge as there are over 8 million children who are candidates for AAC. A need for an introductory training course on AAC, which can be accessed by university students continent-wide, was identified. What this paper adds to existing knowledge An AAC curriculum was developed and integrated into an ITS, an online programme allowing interactive learning through asynchronous teaching. Students from four African countries completed the AAC ITS curriculum. The curriculum was positively received by the students and statistically significant changes in knowledge were identified. What are the practical and clinical implications of this work? This feasibility study shows that the use of an ITS is an effective means of providing AAC training to university students in these African countries. The results provide a valuable contribution toward ensuring the equitable distribution of AAC training opportunities in the African context. This will have a significant positive impact on those who are candidates for AAC.
Patients may receive Td or Tdap IM prior to undergoing leukapheresis. Patients receive FRalphaDCs ID on day 1 of each cycle. Cycles repeat every 21 days for cycles 1-5 and then repeat every 91 days for cycles 6-12 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo biopsy prior to apheresis and optionally at end of treatment, and blood sample collection, CT and/or MRI throughout the study.
KT was applied once a week, 6 times in total. Exercises were performed for all patients for 5 weeks 5 days a week, 3 sets 15 repetitions each day.
A method for isolating a non toxic, high molecular weight polysaccharide  igen from the crude slime of a Pseudomonas aeruginosa culture, and a method for inducing immunity in a host to said live organisms is described. The slime is initially prepared for the isolation procedure by separating the bacterial cells from the slime and dissolving the slime in a phosphate buffer solution. Dissolved contaminating nucleic acids are then precipitated and separated from solution. A lipid A portion of the contaminating lipopolysaccharide constituent is then removed and precipitated by acetic acid hydrolysis, and the remaining lipids present are extracted with chloroform. Nearly all of the residual nucleic acids are then removed by digestion with nucleases, and the remaining protein extracted with phenol. The aqueous and phenol layers are then separated, and the aqueous layer applied to a gel filter to isolate the antigen by column chromatography. The antigen appears in the void volume. A vaccine containing the polysaccharide antigen of this invention has been successfully tested and found to be non toxic and highly effective in inducing an immune response to the organism in a host.
The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults.

In Phase II/III clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with fluconazole at doses up to 15 mg/kg/day for up to 1,616 days. Thirteen percent of children experienced treatment- related adverse events. The most commonly reported events were vomiting (5%), abdominal pain (3%), nausea (2%) and diarrhea (2%). Treatment was discontinued in 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase.

To report suspected ADVERSE REACTIONS, contact HARRIS Pharmaceutical at 1-800-983-4708 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Participants will receive nipocalimab dose 1 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
Sleep disorders involve significant increases in morbidity and mortality, particularly in those over 60 years. Sleep apnea is the leading identifiable cause of hypertension, which is the main cause of cardiovascular disease. Some degree of sleep apnea is present in up to 95% of the elderly. Intraoral mandibular advancement appliances reduce the number of apneas and hypopneas.

We hypothesized that reducing the number of sleep apnea events through oral appliances is effective in preventing high blood pressure and other consequences of sleep apnea in the elderly in the public health system setting. In this superiority parallel, randomized, and double-blinded study we will compare the effect of an intraoral appliance with mandibular advancement to a placebo device without mandibular advancement in preventing high blood pressure and other consequences of sleep apnea in the elderly. The duration of intervention will be of 12 months, with assessments at three, six months, and 12 months.
Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
The process comprises reaction of a 2-acetamido-2-desoxy-3-O-sulphonyl substd. hexapyranoxide of formula (II) (where R7 = various radicals and R1,2,4,5 = various types of radicals) with an alkali metal azide in a solvent or mixt. of inert solvents in the presence of a tetraalkyl ammonium salt. Subsequent catalytic redn. and reaction with a deriv. of alpha-halocarboxylic acid of formula X-CHR3-CO2R4 (III), (where X = halogen; R3 = H or lower alkyl) yields derivs. of muramic acid of formula (I).
A radiation susceptible agent of low-oxide cancer cells having extracts of ginko leaves as an active ingredient, wherein susceptibility for radiation of low-oxide cancer cells are increased, for thereby improving radiation therapy efficiency without little side effect so that it becomes possible to use for a continuous 6 to 8 week period of the radiation therapy. Refined extract of ginko leaves containing 24% or more ginko flavon glycoside and 6% of terfenracton system compounds is prepared. After the extract 50mg and mannitol 100mg as a solvent agent are put in a vial and dissolved, the result product is bacteria-filtered by means of 0.2 micrometer membrane and dried by freezing under a sterile condition to be powdered for preparing an injecting agent. The prepared powder injecting agent exhibits relatively strong acidity of 2.5-3.0 when dissolving.  Therefore, phosphomonohydrosodium 26mg is dissolved in distilled water 3mL, filtered by means of a membrane filter of 0,22 micrometer, and sterilized at 120 deg. C for 25 minutes, obtaining a buffering agent.Such buffered extract of ginko leaves is used after dissolving the injecting agent by solvent for administration.
The proportion of older adults is on the rise in Canada, with the fastest growth recorded among those seventy years of age or older. The prevalence of cardiovascular risk factors (CVRF) such as diabetes, hypertension, and high cholesterol increases drastically with age. Individuals with CVRF often show impaired cognition, such as attention and memory deficits. In healthy older adults, exercise training and cognitive stimulation can help enhance cognitive performances. More precisely, combined intervention, including physical and cognitive training, has shown beneficial effects on cognition in older adults without cognitive impairment and with mild cognitive impairment. However, the effect of such programs on cognition in individuals with CVRF is not well documented. This project compares the effect of a physical exercise program, including aerobic and resistance training, alone or combined with cognitive training on cognitive performances and brain imaging outcomes in individuals with CVRF and healthy controls.
BACKGROUND: Minimally invasive esophagectomy (MIE) has been increasingly performed for locally advanced esophageal cancer in place of open transthoracic esophagectomy (OE). This study explored the significance of MIE for esophageal squamous cell carcinoma (ESCC), focusing mainly on the depth of primary esophageal tumors.
METHODS: This study retrospectively assessed short- and long-term outcomes of patients who underwent esophagectomy for ESCC from 2005 through 2021. The inverse probability of the treatment-weighting (IPTW) method was used to compare the outcomes between OE and MIE. The outcomes also were evaluated in the subgroups stratified by cT category.
RESULTS: Among 1117 patients, 447 (40%) underwent OE and 670 (60%) underwent MIE. After IPTW adjustment, the incidence of any postoperative complications was significantly higher in the OE group than in the MIE group (60.8% vs 53.7%; p = 0.032), whereas the R0 resection rate was significantly higher in the MIE group (98.6% vs 92.7%; p < 0.001). The MIE group showed better 3 year overall and cancer-specific survival than the OE group (p < 0.001). The incidence of locoregional recurrence within the surgical field was significantly more frequent in the OE group (p < 0.001). In the subgroup analysis stratified by cT category, the R0 resection rate was significantly higher and the incidence of locoregional recurrence was lower in the MIE group among the patients with cT3-4 tumors. In the patients with cT1-2 tumors, MIE showed no significant benefit over OE.
CONCLUSIONS: For the patients with cT3-4 tumors, MIE showed fewer postoperative complications, better locoregional control, and better prognosis than OE. Compared with OE, MIE is beneficial, especially for locally advanced ESCC.
The research was conducted to examine the effect of logotherapy-based intervention practiced to depressed patients on depression, psychological pain and meaning of life.

The research is in a quasi-experimental research design with pre-test post-test follow-up measurement, control group. Sample selection was carried out in two stages, and in the first stage, 48 patients diagnosed with depression between September 2020 and September 2022 were referred to the researcher by the polyclinic physician. The patients were evaluated within the scope of the inclusion criteria of the study, and 32 patients with a diagnosis of depression, aged 18-65 years, voluntarily aged between 18-65, who scored 17 points or more from the Beck Depression Inventory, were accepted into the study. Patients were assigned to intervention and control groups, respectively. A total of 28 patients, 12 intervention and 16 control groups, completed the study. "Descriptive Information Form", "Beck Depression Inventory", "Psychache Scale" and "Meaning of Life Questionnaire" were used as data collection tools in the study. Online logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week. In order to evaluate the effect of logotherapy-based intervention, Beck Depression Inventory, Psychache Scaleand Meaning of Life Questionnaire were administered to all individuals in the sample group at time series points (pretest, posttest, follow-up test at 3rd month). In the analysis of the data, descriptive statistics, independent t-test, chi-square analysis, analysis of variance in repeated measurements, Bonferroni correction were applied.
The invention discloses a quantum dot modified protein vaccine and a preparation method and application thereof, and relates to the field of nano materials and biomedicine. The raw materials of the quantum dot modified protein vaccine comprise quantum dot particles and antigen protein, wherein the surfaces of the quantum dot particles comprise biocompatible functional groups, and the antigen protein and the functional groups act to enable the protein to be wound on the surfaces of the quantum dot particles through non-covalent bond action. In the application, the spatial conformation of the antigen protein can be changed by modifying the antigen protein through quantum dots, and the conformational modifications lead to the remarkable enhancement of the immunogenicity of normal protein and simultaneously cause the dysfunction of immunosuppressive protein on cancer cells. The probability of specific recognition of the protein is enhanced. The quantum dot modified protein vaccine can greatly improve the immunogenicity of protein, and further has better immune activation characteristic, and the preparation method is simple and the operation condition is mild. The obtained quantum dot modified protein vaccine can be applied to personalized immunotherapy of cancers.
Hay nets are a commonly used management practice to increase intake time and reduce hay waste but may impact horse health. The objectives were to compare hay usage, dental wear, and dental conditions between horses fed with (NET) or without (CON) hay nets during a 2-year cross-over study. In September 2021, 13 mature adult horses were blocked by bodyweight (BW) and randomly assigned to the NET or CON treatments for one year. After one year (September 2022), horses switched treatments and the trial concluded in September 2023. Horses were housed in adjacent dry lots with shelter, ad libitum water, and free choice access to round bales with or without hay nets (4.45 cm openings). Blinded dental work, including incisor length measurements and recording of dental abnormalities and conditions, and recording of horse BW and body condition score (BCS) were completed in September 2021, 2022, and 2023. Digital images were taken monthly to determine rostral oral cavity scores (ROCS). Round bales were weighed prior to being placed in the dry lot and the date fed was recorded to calculate hay usage. Significance was set at P≤0.05. Horse BW, BCS, and hay usage were greater in horses consuming hay without hay nets (P<0.05). No differences were observed in incisor length, presence of incisor bevels, ROCS, or dental abnormalities and conditions (P>0.05). These data suggest that hay nets do not result in negative impacts on dental health but can reduce hay usage and help to control horse BW and BCS.
Subjects randomized in the Placebo Arm will take one placebo capsule daily. Each capsule will also contain 32 mg of riboflavin as a tracer substance for tracking compliance.
It has been demonstrated in studies utilising functional brain MRI and EEG that following ACLR, individuals have increased activation of the visual system during simple motor tasks as compared to healthy controls. This is suggested to represent an increased reliance on the visual system during motor planning and execution. Increased reliance on the visual system may negatively affect an individual's ability to respond to sporting situations which are often chaotic in nature, resulting in an inappropriate movement technique being employed. This may then result in an increased risk of reinjury. However, no study to date has been able to assess how visual reliance affects change of direction biomechanics.

The study will recruit individuals who are 7 months post-ACLR and intend on returning to multi-directional field sport. Individuals will complete a stepping down task (eyes open versus eyes closed) to identify participants who are reliant on their visual system. Participants will then complete a 90 deg change of direction task in a planned and then unplanned condition. Those who are visually reliant will be compared to those who are aren't with regards to their unplanned change of direction biomechanics and also the change in their biomechanics from a planned to unplanned condition.
Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
Heat therapy (HT) is an emerging non-invasive approach that has been shown to enhance vascular function of the leg in old individuals. The objective of this randomized, controlled study is to evaluate the benefits of participating for 8 weeks in a home-based daily treatment with heat therapy (HT) or a thermoneutral control intervention, as assessed by vascular function, walking tolerance and quality of life. The central hypothesis of this study, based on preliminary data, is that exposure to HT will enhance the oxygenation of calf muscles during exercise and as a result, the onset of pain will be delayed and walking performance will be enhanced. The duration (8 weeks) was chosen based on the recent report of Brunt and co-workers that the improvement in endothelial function promoted by repeat HT in sedentary individuals peaks at 8 weeks following the onset of treatment. Heat Therapy will be applied daily for 90 minutes using water-circulating 'pants' connected to a water pump. Outcomes will be assessed at the halfway point (end of week 4), at the completion of the intervention (end of week 8) and 4 weeks after the end of the intervention (week 12).
The invention relates to a composition for treating colorectal cancer, which consists of marsdenia tenacissima G and 5-FU. The invention also provides the use of the colorectal cancer composition. The invention has the advantages that: the invention adopts the combined medication of marsdenia tenacissima G (50 mu M) and 5-FU (5 mu M), which can effectively inhibit the proliferation of RKO cells of colorectal cancer. Compared with a single administration group, the combined administration can block cells in the G0/G1 stage, enhance the sensitivity of cancer cells and promote the apoptosis of colorectal cancer cells. The experimental protocol confirms that: the combination of marsdenia tenacissima G and fluorouracil has the effect of inhibiting the proliferation of colorectal cancer cells; the blocking effect of the combination of marsdenia tenacissima G and fluorouracil on cell cycle of colorectal cancer; the marsdenia tenacissima G combined with fluorouracil induces the apoptosis of colorectal cancer cells. The invention has the prospect of developing clinical combined medicine.
Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
This is a phase II signal-searching study in a range of tumor types with the potential to identify novel tumor indications for combination therapy with olaparib that can subsequently be explored in dedicated studies. Patients will be enrolled in this study based on molecular markers from genetic profiling performed on their tumors prior to study entry (outside of protocol). The trial will also identify genetic determinants of response and resistance.

Patients with tumors harboring damaging mutations in Homologous - DNA repair (HDR) genes or mutations such as ATM, CHK2, MRN (MRE11/NBS1/RAD50), CDKN2A/B and APOBEC will be treated with olaparib or olaparib and AZD6738. Enrollment to the olaparib monotherapy arm will be completed prior to commencement of enrollment to the olaparib and AZD6738 arm. Patients with tumors harboring IDH1/IDH2 mutations will be treated with olaparib. Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
Patients in the breathing exercise practice group will have breathing exercise practice for 15-20 minutes half an hour before the angiography procedure. The breathing exercise application will be applied to the patients face to face by the researcher.